Tenosynovial Giant Cell Tumor Clinical Trial
Official title:
A Phase 2, Adaptive, Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Intravenous AMB-05X in Subjects With Tenosynovial Giant Cell Tumor
The purpose of this Phase 2, open-label, multiple-dose, dose-escalation study is to evaluate intravenous AMB-05X in the treatment of subjects with TGCT.
AMB-05X drug substance is a human monoclonal antibody against the colony-stimulating factor 1 receptor (CSF1R). ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04488822 -
A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT
|
Phase 3 | |
Active, not recruiting |
NCT01207492 -
Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor
|
Phase 2 | |
Completed |
NCT04526704 -
Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib
|
Phase 4 | |
Active, not recruiting |
NCT05059262 -
Study of Vimseltinib for Tenosynovial Giant Cell Tumor
|
Phase 3 | |
Active, not recruiting |
NCT04731675 -
An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee
|
Phase 2 | |
Completed |
NCT02371369 -
Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)
|
Phase 3 | |
Recruiting |
NCT04703322 -
A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan
|
Phase 2 | |
Completed |
NCT02471716 -
Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor
|
Phase 1/Phase 2 | |
Recruiting |
NCT04635111 -
A Long-term Study Evaluating Hepatotoxicity Associated With TURALIOâ„¢ (Pexidartinib) Treatment
|
||
Recruiting |
NCT05349643 -
A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT
|
Phase 2 | |
Recruiting |
NCT04192344 -
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
|
Phase 1 | |
Terminated |
NCT02673736 -
A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor
|
Phase 1 | |
Active, not recruiting |
NCT03069469 -
Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
|
Phase 1/Phase 2 | |
Terminated |
NCT01804530 -
Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT05804045 -
Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)
|
Phase 3 |